Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031358 | 0.83 | HRH1 (0.50) | HRH1OPRD1OPRK1RBP4HTR2A | |
| Fumaric Acid SCHEMBL6439581 | 0.82 | HRH1 (0.59) | HRH1CALCRLHTR2AHTR2C | |
| SCHEMBL6030123 | 0.78 | HRH1 (0.60) | HRH1CALCRLHTR2AHTR2CSIGMAR1 | |
| SCHEMBL6031570 | 0.74 | HRH1 (0.50) | HRH1OPRD1OPRK1 | |
| SCHEMBL6029703 | 0.69 | HRH1 (0.77) | HRH1OPRD1OPRK1RBP4HTR2A | |
| SCHEMBL6031770 | 0.69 | HRH1 (0.47) | HRH1OPRD1OPRK1HTR2A | |
| SCHEMBL6031742 | 0.68 | HRH1 (0.56) | HRH1OPRD1OPRK1 | |
| SCHEMBL6030027 | 0.68 | HRH1 (0.56) | HRH1OPRD1OPRK1 | |
| SCHEMBL6031874 | 0.68 | SIGMAR1 (0.49) | HRH1HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL6030115 | 0.67 | HRH1 (0.51) | HRH1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | claimed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | claimed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | HRH1 35/4885CALCRL 2041/4885OPRD1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.